Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

New Contract Win

12 Jun 2007 07:00

Marchpole Holdings PLC12 June 2007 MARCHPOLE HOLDINGS PLC Exclusive Jeans Partnership with Lee Cooper Marchpole Holdings plc, (LSE: MPH), the fast growing fashion brand managementgroup, is pleased to announce that its wholly-owned subsidiary Jean Charles deCastelbajac ("JCC") has signed a long term partnership agreement with Lee CooperInc. ('Lee Cooper'), the global denim brand. Under the terms of the agreement, which is for an initial period of five years,two new designer denim lines will be launched in partnership with Lee Cooper forthe Spring/Summer 2008 season. These will be the only premium denim linesoffered by Lee Cooper. JCC will receive royalties on all wholesale and retailsales. All marketing and development of this venture will be jointly funded. JCC will design the main line, branded "JC-DC". This exclusive collection formen and women, themed around contemporary British 60s rock icons, will targetthe younger end of the market, and initially will be distributed through 250 LeeCooper retail stores and JCC flagship stores worldwide. In total, Lee Cooper hassome 500 retail stores. Alongside the mainline collection JCC will design a high-end denim collection,JC de Castelbajac, with a couture finish and targeting existing JCC customers.This collection will be sold in JCC flagship stores worldwide and also top endLee Cooper stores. Michael Morris, Marchpole Executive Deputy Chairman commented: "We are delightedto sign this agreement with Lee Cooper, one of the world's original denimcompanies. The partnership is yet another step in broadening the customer baseof Jean Charles De Castelbajac, into the lucrative denim market. We believe thatthis partnership is a great cultural and strategic fit for both brands and welook forward to a long and successful relationship with Lee Cooper." - ends - For further information, please contact: Bell Pottinger Corporate & Financial 020 7861 3232David Rydell/Emma Kent/Amy Rajendran Marchpole Holdings plc 020 7908 7700Michael Morris, Executive ChairmanJohn Harrison, Finance Director Note to Editors: - Marchpole Holdings plc ("Marchpole") is an international brandmanagement group that designs, produces and sells clothing and accessories fornine globally recognised fashion labels. It operates in all of the world's mainmarkets - UK, mainland Europe, Middle East, Asia and the USA - Its respected brands include Boateng, Emmanuel Ungaro, Ungaro, JeanCharles de Castelbajac ("JCC"), Jean Charles de Castelbajac / Rossignol, JeanCharles de Castelbajac/Okaidi, Jean Charles de Castelbajac / New Era, JeanCharles de Castelbajac/Lee Cooper and Homebody - Marchpole is renowned for its integrated approach to brandmanagement, taking a brand from concept to design studio to the customerinterface. It is not a clothing manufacturer - The Group has grown considerably in the past four years, from alicensee with one core license (YSL menswear) - to today's internationalbusiness that manages its brands across a multitude of clothing lines andaccessories - Marchpole's acquisition (March 2006) of Moda America - the USlicensee for leading designer Emanuel Ungaro - provided further growthopportunities in the UK and America and strengthened the Company's relationshipwith Ungaro - The acquisition also enabled the Company to launch the Ungaro brand,already established by Marchpole in Europe and Asia, into the US, Canada andSouth America. The acquisition has also enabled the Company to re-launch JCCinto America. - In March 2007 Marchpole acquired 100% of Greenmark Limited, an importer and wholesaler of ladies shoes who currently supply in excess of 2.5 million pairs of shoes per annum. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Sep 20191:00 pmRNSNotice of Results
6th Sep 20197:00 amRNSBlock listing Interim Review
4th Sep 20191:00 pmRNSMereo announces phase 2b data at ASBMR Meeting
16th Aug 20191:51 pmRNSDirector/PDMR Shareholding
15th Aug 20194:59 pmRNSPDMR Shareholding
12th Aug 20194:41 pmRNSSecond Price Monitoring Extn
12th Aug 20194:35 pmRNSPrice Monitoring Extension
9th Aug 20194:35 pmRNSPrice Monitoring Extension
31st Jul 201912:51 pmRNSDirector Declaration
25th Jul 20194:56 pmRNSPDMR Shareholding
24th Jul 201910:08 amRNSDirector/PDMR Shareholding
19th Jul 20191:21 pmRNSDirector/PDMR Shareholding
16th Jul 20191:00 pmRNSAppointment of Richard Francis
15th Jul 20191:00 pmRNSSuccessful Type B Meeting with U.S. FDA
8th Jul 20193:54 pmRNSHolding(s) in Company
3rd Jul 20194:41 pmRNSSecond Price Monitoring Extn
3rd Jul 20194:35 pmRNSPrice Monitoring Extension
27th Jun 20193:33 pmRNSHolding(s) in Company
26th Jun 20194:36 pmRNSHolding(s) in Company
21st Jun 20191:00 pmRNSConversion of loan note and issue of equity
20th Jun 20197:00 amRNSResult of AGM
13th Jun 20191:00 pmRNSUpdate on Etigilimab (TIGIT) Partnership
30th May 20197:00 amRNSPositive early 6 month data
23rd May 20194:11 pmRNSDirector/PDMR Shareholding
22nd May 20199:45 amRNSPDMR Shareholding
21st May 20193:08 pmRNSDirector/PDMR Shareholding
20th May 20197:00 amRNSNotice of AGM
8th May 20191:53 pmRNSDirector/PDMR Shareholding
7th May 20197:00 amRNSIssue of Warrants
7th May 20197:00 amRNSRe-release: Intention to Purchase Shares
3rd May 20195:00 pmRNSIntention to Purchase Shares by Trustee of EBT
3rd May 20192:02 pmRNSDirector/PDMR Shareholding
1st May 20193:47 pmRNSDirector/PDMR Shareholding
30th Apr 20193:15 pmRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSDirector/PDMR Shareholding
30th Apr 20197:00 amRNSPublication of Annual Report and Accounts
29th Apr 20197:00 amRNSPrelims Results for year ended December 31 2018
26th Apr 20193:01 pmRNSDirector/PDMR Shareholding
25th Apr 20193:36 pmRNSHolding(s) in Company
25th Apr 20193:29 pmRNSHolding(s) in Company
24th Apr 20192:30 pmRNSAdmission to Trading
23rd Apr 20192:25 pmRNSCompletion of Merger
18th Apr 20197:00 amRNSMerger Update
15th Apr 20197:00 amRNSSuccessful end of Phase 2 Meeting with FDA
21st Mar 20197:00 amRNSPublication of Form F-4
15th Mar 201911:45 amRNSUpdate on Proposed Combination of Mereo & OncoMed
13th Mar 201911:00 amRNSMereo CEO appointed NED of Elanco Animal Health
6th Mar 20197:00 amRNSBlock Listing Interim Review
5th Mar 20191:32 pmRNSMereo to present at Cowen and Company Conference
22nd Feb 20191:50 pmRNSUpdate on Proposed Transaction with OncoMed

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.